207 related articles for article (PubMed ID: 10664252)
1. In vitro effect of multidrug resistance modifiers on idarubicinol efflux in blasts of acute myeloid leukemia.
Schröder JK; Kasimir-Bauer S; Seeber S; Scheulen ME
J Cancer Res Clin Oncol; 2000 Feb; 126(2):111-6. PubMed ID: 10664252
[TBL] [Abstract][Full Text] [Related]
2. Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance.
Ross DD; Doyle LA; Yang W; Tong Y; Cornblatt B
Biochem Pharmacol; 1995 Nov; 50(10):1673-83. PubMed ID: 7503771
[TBL] [Abstract][Full Text] [Related]
3. Modulation of multidrug resistance by BIBW22BS in blasts of de novo or relapsed or persistent acute myeloid leukemia ex vivo.
Schröder J; Esteban M; Müller MR; Kasimir-Bauer S; Bamberger U; Heckel A; Seeber S; Scheulen ME
J Cancer Res Clin Oncol; 1996; 122(5):307-12. PubMed ID: 8609155
[TBL] [Abstract][Full Text] [Related]
4. Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells.
Berman E; McBride M
Blood; 1992 Jun; 79(12):3267-73. PubMed ID: 1596567
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of daunorubicin accumulation, retention, and cytotoxicity by verapamil or cyclosporin A in blast cells from patients with previously untreated acute myeloid leukemia.
Ross DD; Wooten PJ; Sridhara R; Ordóñez JV; Lee EJ; Schiffer CA
Blood; 1993 Aug; 82(4):1288-99. PubMed ID: 8102561
[TBL] [Abstract][Full Text] [Related]
6. Restoring uptake and retention of daunorubicin and idarubicin in P170-related multidrug resistance cells by low concentration D-verapamil, cyclosporin-A and SDZ PSC 833.
Michieli M; Damiani D; Michelutti A; Candoni A; Masolini P; Scaggiante B; Quadrifoglio F; Baccarani M
Haematologica; 1994; 79(6):500-7. PubMed ID: 7896208
[TBL] [Abstract][Full Text] [Related]
7. Idarubicin overcomes P-glycoprotein-related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines.
Roovers DJ; van Vliet M; Bloem AC; Lokhorst HM
Leuk Res; 1999 Jun; 23(6):539-48. PubMed ID: 10374847
[TBL] [Abstract][Full Text] [Related]
8. The influence of intracellular idarubicin and daunorubicin levels on drug cytotoxicity in childhood acute leukemia.
Styczyński J; Wysocki M; Debski R; Kurylak A; Balwierz W; Rokicka-Milewska R; Matysiak M; Balcerska A; Kowalczyk J; Wachowiak J; Sońta-Jakimczyk D; Chybicka A
Acta Biochim Pol; 2002; 49(1):99-107. PubMed ID: 12136962
[TBL] [Abstract][Full Text] [Related]
9. Flow cytometric study of idarubicin and daunorubicin accumulation and the effect of verapamil in leukemic cell lines and fresh cells from patients with acute non-lymphoblastic leukemia.
Boiron JM; Belloc F; Montastruc M; Cony-Makhoul P; Dumain P; Marit G; Mahon FX; Puntous M; Lopez F; Lacombe F
Leuk Res; 1994 May; 18(5):313-8. PubMed ID: 8182921
[TBL] [Abstract][Full Text] [Related]
10. Comparison of idarubicin and daunorubicin regarding intracellular uptake, induction of apoptosis, and resistance.
Lotfi K; Zackrisson AL; Peterson C
Cancer Lett; 2002 Apr; 178(2):141-9. PubMed ID: 11867198
[TBL] [Abstract][Full Text] [Related]
11. Cellular pharmacology of idarubicinol in multidrug-resistant LoVo cell lines.
Toffoli G; Corona G; Simone F; Gigante M; De Angeli S; Boiocchi M
Int J Cancer; 1996 Jul; 67(1):129-37. PubMed ID: 8690513
[TBL] [Abstract][Full Text] [Related]
12. D-verapamil downmodulates P170-associated resistance to doxorubicin, daunorubicin and idarubicin.
Damiani D; Michieli M; Michelutti A; Melli C; Cerno M; Baccarani M
Anticancer Drugs; 1993 Apr; 4(2):173-80. PubMed ID: 8098233
[TBL] [Abstract][Full Text] [Related]
13. p170-dependent multidrug resistance. Restoring full sensitivity to idarubicin with verapamil and cyclosporin A derivatives.
Michieli M; Damiani D; Michelutti A; Melli C; Russo D; Fanin R; Baccarani M
Haematologica; 1994; 79(2):119-26. PubMed ID: 7914881
[TBL] [Abstract][Full Text] [Related]
14. Comparative activity of idarubicin and idarubicinol in combination with cyclosporin A in multidrug-resistant leukemia cells.
Tolomeo M; Gancitano RA; Musso M; Porretto F; Perricone R; Abbadessa V; Cajozzo A
Cancer Chemother Pharmacol; 1996; 39(1-2):157-61. PubMed ID: 8995514
[TBL] [Abstract][Full Text] [Related]
15. Idarubicin and idarubicinol are less affected by topoisomerase II-related multidrug resistance than is daunorubicin.
Fukushima T; Inoue H; Takemura H; Kishi S; Yamauchi T; Inai K; Nakayama T; Imamura S; Urasaki Y; Nakamura T; Ueda T
Leuk Res; 1998 Jul; 22(7):625-9. PubMed ID: 9680113
[TBL] [Abstract][Full Text] [Related]
16. Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia.
Pea F; Damiani D; Michieli M; Ermacora A; Baraldo M; Russo D; Fanin R; Baccarani M; Furlanut M
Eur J Clin Pharmacol; 1999 Jul; 55(5):361-8. PubMed ID: 10456485
[TBL] [Abstract][Full Text] [Related]
17. Comparison of mechanisms responsible for resistance to idarubicin and daunorubicin in multidrug resistant LoVo cell lines.
Toffoli G; Simone F; Gigante M; Boiocchi M
Biochem Pharmacol; 1994 Nov; 48(10):1871-81. PubMed ID: 7986198
[TBL] [Abstract][Full Text] [Related]
18. Comparison of idarubicin and daunorubicin and their main metabolites regarding intracellular uptake and effect on sensitive and multidrug-resistant HL60 cells.
Tidefelt U; Prenkert M; Paul C
Cancer Chemother Pharmacol; 1996; 38(5):476-80. PubMed ID: 8765443
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of idarubicin, a derivative of daunorubicin, against drug sensitive and resistant P388 leukemia.
Tsuruo T; Oh-Hara T; Sudo Y; Naito M
Anticancer Res; 1993; 13(2):357-61. PubMed ID: 8517647
[TBL] [Abstract][Full Text] [Related]
20. P-glycoprotein and multidrug resistance-associated protein, but not lung resistance protein, lower the intracellular daunorubicin accumulation in acute myeloid leukaemic cells.
Borg AG; Burgess R; Green LM; Scheper RJ; Liu Yin JA
Br J Haematol; 2000 Jan; 108(1):48-54. PubMed ID: 10651723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]